European Community

European Community (Ec)

Institut National De La Sante Et De La Recherche Medicale

Universitat Heidelberg

The European Atomic Energy Community (Euratom), Represented by the European Commission

The European Community, Represented by the European Commission

The European Union, Represented by the European Commission

Christos Apostolidis

Roger Molinet

Lothar Koch

Jacques Van Geel

Ali Ouadi

Alfred Morgenstern

Willem Janssens

Uwe Haberkorn

Frederik Giesel

Jean-François Gestin

Clemens Kratochwil

Hermann Schweickert

Klaus Luetzenkirchen

Josef M&ouml;llenbeck

Michel Ougier

John McGinley

Jean-Francois Gestin

Frank Bruchertseifer

Bruno Brandalise

Klaus Lützenkirchen

The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a dosage of from 25 kBq to 400 kBq/kg of body weight of said patient or wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a unitary dosage of from 3 MBq to 30 MBq to said patient.

Treatment of PMSA expressing cancers

Methods of using Th-226 or mother radionuclides thereof, namely U-230 or Th-226, in medicine. These radionuclides are particularly appropriate for the treatment of human and/or non-human mammals, in particular for therapeutic, diagnostic (detection/imaging), prophylactic and pain palliation purposes. These radionuclides may be used in various forms for treatment and/or diagnostic purposes, in particular in cationic form or in the form of radioconjugates or bone-targeting complexes. Methods of making such radionuclides.

Radionuclides for medical use

The invention concerns a ligand comprising wherein n is an integer from 1 to 5, X represents &#x2014;NO, &#x2014;NH, &#x2014;NCS, &#x2014;NHCOCH-Z. NHCO&#x2014;W&#x2014;COCNHS, &#x2014;NH-Q, &#x2014;NHCS-Q, &#x2014;NHCOCH-Q, or &#x2014;NHCO(CH)m ?-Q where Q is an hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, Y is COH or POHW is &#x2014;(CH)&#x2014; m is an integer from 1 to 10. Z is chloride, bromide or iodine 

Bifunctional chelating agent

The invention concerns a ligand comprising (I) wherein n is an integer from 1 to 5 Y is CO2H or PO3H2T represents &#x2014;X or -phenyl-X, wherein X represents NO2, NH2, NCS, NHCOCH2-Z, NHCO&#x2014;W&#x2014;COCNHS, &#x2014;NH-Q, &#x2014;NHCS-Q, &#x2014;NHCOCH2-Q, or NHCO(CH2)m-Q where Q is a hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, W is &#x2014;(CH2)m- m is an integer from 1 to 10 Z is chloride, bromide or iodine 

Bifunctional chelating agent for actinium

This invention relates to a method and an apparatus for preparing Bi-213 to be integrated in a radioimmunocojugate for human therapeutic use. According to the invention the method comprises the sequence of steps as follows: a) an ampoule containing colloid-free actinium-225, obtained from drying an actinium nitrate solution, is loaded into a container provided with radiation panels ; b) a dissolving medium is poured into the ampoule ; c) the solution obtained in the ampoule is transferred into an ion exchange column ; d) an elution medium is circulated through the column ; e) the eluate containing eluted Bi-213 is pumped towards a vial for quantification and quality control.

Method and apparatus for preparing Bi-213 for human therapeutic use

This invention refers to a method for producing Actinium-225, comprising the steps of preparing a target (,) containing Radium-226, of irradiating this target with protons in a cyclotron and of chemically separating Actinium from the irradiated target material thereafter. According to the invention the proton energy in the cyclotron is adjusted such that the energy incident on the Ra-226 is between 10 and 20 MeV, preferably between 9 14 and 17 MeV. By this means the yield of production of the desired isotope Ac-225 is enhanced with respect to other radioisotopes.

Method for producing Ac-225 by irradiation of Ra-226 with protons

Growing community of inventors

Heidelberg, Germany

Christos Apostolidis